Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Human RNAi Therapy Jumps Hurdle

  |  

The authors identified only one clear adverse event in the human study: a moderate infusion-related reaction in the patient who received 0.5 mg/kg of ALN-TTR02. Mild-to-moderate infusion-related reactions occurred in 20.8% of patients receiving ALN-TTR01 and 7.7% of patients receiving ALN-TTR02.

Dr. Suhr expressed hope that it may be possible to bring the RNAi therapy to market in 2017 or 2018.

ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Pullen is a medical writer based in the Chicago area.

Reference

  1. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819-829.

 

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Amyloidosis Is Often Underdiagnosed, Undertreated

    CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…

    An Amylodosis Warning & New Drug Hope

    SAN DIEGO—Treatments do exist that can improve the prospects of a patient with the rare disease amyloidosis, but only if clinicians keep the disease in mind and treat the patient before it’s too late, an expert said at the 2017 ACR/ARHP Annual Meeting this past November. He also discussed research that may be close to…

    2015 ACR/ARHP Annual Meeting: Treatments for Transthyretin-Related Amyloidosis Generate Interest from Researchers, Pharmaceuticals

    SAN FRANCISCO—Treatment for transthyretin-related amyloidosis (ATTR) is generating more interest from academic researchers and the pharmaceutical industry, with encouraging early results using a multi-pronged therapeutic approach, a researcher said at a review course held before the 2015 ACR/ARHP Annual Meeting. Amyloidoses are a rare and potentially deadly family of diseases in which misfolded protein builds…